{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:15:22Z","timestamp":1781655322075,"version":"3.54.5"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,20]]},"DOI":"10.7759\/cureus.17320","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T11:16:04Z","timestamp":1629458164000},"source":"Crossref","is-referenced-by-count":5,"title":["The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC)"],"prefix":"10.7759","author":[{"given":"Ajit","family":"Venniyoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Aziz","family":"Al Farsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassim","family":"Al Bahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan N","year":"2019","unstructured":"Stefan N, H\u00e4ring H-U, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019, 7:313-24. 10.1016\/s2213-8587(18)30154-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka AC","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020, 323:1175-83. 10.1001\/jama.2020.2298","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2019.09.08","article-title":"Epidemiology of non-alcoholic and alcoholic fatty liver diseases","volume":"5","author":"Mitra S","year":"2020","unstructured":"Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020, 5:16. 10.21037\/tgh.2019.09.08","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi Z","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al.. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018, 15:11-20. 10.1038\/nrgastro.2017.109","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000502","article-title":"Nonalcoholic steatohepatitis: the new frontier for liver transplantation","volume":"23","author":"Bzowej NH","year":"2018","unstructured":"Bzowej NH. Nonalcoholic steatohepatitis: the new frontier for liver transplantation. Curr Opin Organ Transplant. 2018, 23:169-74. 10.1097\/MOT.0000000000000502","journal-title":"Curr Opin Organ Transplant"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R008896","article-title":"Genetic determinants of hepatic steatosis in man","volume":"52","author":"Hooper AJ","year":"2011","unstructured":"Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J Lipid Res. 2011, 52:593-617. 10.1194\/jlr.R008896","journal-title":"J Lipid Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2535","article-title":"Acquired generalized lipodystrophy: a new cause of anti-PD-1 immune-related diabetes","volume":"42","author":"Jehl A","year":"2019","unstructured":"Jehl A, Cugnet-Anceau C, Vigouroux C, et al.. Acquired generalized lipodystrophy: a new cause of anti-PD-1 immune-related diabetes. Diabetes Care. 2019, 42:2008-10. 10.2337\/dc18-2535","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1089\/pancan.2020.0006","article-title":"Nonalcoholic fatty liver disease after pancreaticoduodenectomy for a cancer diagnosis","volume":"7","author":"McGhee-Jez AE","year":"2021","unstructured":"McGhee-Jez AE, Chervoneva I, Yi M, et al.. Nonalcoholic fatty liver disease after pancreaticoduodenectomy for a cancer diagnosis. J Pancreat Cancer. 2021, 7:23-30. 10.1089\/pancan.2020.0006","journal-title":"J Pancreat Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14858","article-title":"Unraveling the role of hypothyroidism in non-alcoholic fatty liver disease pathogenesis: correlations, conflicts, and the current stand","volume":"13","author":"Gor R","year":"2021","unstructured":"Gor R, Siddiqui NA, Wijeratne Fernando R, Sreekantan Nair A, Illango J, Malik M, Hamid P. Unraveling the role of hypothyroidism in non-alcoholic fatty liver disease pathogenesis: correlations, conflicts, and the current stand. Cureus. 2021, 13:e14858. 10.7759\/cureus.14858","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam M","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al.. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020, 73:202-9. 10.1016\/j.jhep.2020.03.039","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.02.030","article-title":"Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults [PREPRINT]","author":"Liu J","year":"2021","unstructured":"Liu J, Ayada I, Zhang X, et al.. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults [PREPRINT]. Clin Gastroenterol Hepatol. 2021, S1542-3565(21)00208-1. 10.1016\/j.cgh.2021.02.030","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324162","article-title":"NAFLD in lean individuals: not a benign disease [PREPRINT]","author":"Francque S","year":"2021","unstructured":"Francque S, Wong VW. NAFLD in lean individuals: not a benign disease [PREPRINT]. Gut. 2021, 10.1136\/gutjnl-2021-324162","journal-title":"Gut"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel VT","year":"2018","unstructured":"Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab. 2018, 27:22-41. 10.1016\/j.cmet.2017.08.002","journal-title":"Cell Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13643","article-title":"Global epidemiology of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: what we need in the future","volume":"38 Suppl 1","author":"Ara\u00fajo AR","year":"2018","unstructured":"Ara\u00fajo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S. Global epidemiology of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: what we need in the future. Liver Int. 2018, 38 Suppl 1:47-51. 10.1111\/liv.13643","journal-title":"Liver Int"},{"key":"ref15","article-title":"Obesity in Oman: a major public health challenge","author":"Health Ministry","year":"2021","unstructured":"Health Ministry. Obesity in Oman: a major public health challenge. Ministry of Health, Government of Oman, Oman; 2021."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S300051","article-title":"Clinical and metabolic characteristics of non-alcoholic fatty liver disease patients in Saudi Arabia: data from the Systematic Observatory Liver Disease (SOLID) Registry","volume":"14","author":"Alswat K","year":"2021","unstructured":"Alswat K, Sanai FM, Al-Hamoudi W, et al.. Clinical and metabolic characteristics of non-alcoholic fatty liver disease patients in Saudi Arabia: data from the Systematic Observatory Liver Disease (SOLID) Registry. Diabetes Metab Syndr Obes. 2021, 14:1167-75. 10.2147\/DMSO.S300051","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/sjg.SJG_122_18","article-title":"Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030","volume":"24","author":"Alswat K","year":"2018","unstructured":"Alswat K, Aljumah AA, Sanai FM, et al.. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030. Saudi J Gastroenterol. 2018, 24:211-9. 10.4103\/sjg.SJG_122_18","journal-title":"Saudi J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10182-x","article-title":"Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait [PREPRINT]","author":"Sanai FM","year":"2021","unstructured":"Sanai FM, Al Khathlan A, Al Fadhli A, et al.. Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait [PREPRINT]. Hepatol Int. 2021, 10.1007\/s12072-021-10182-x","journal-title":"Hepatol Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036663","article-title":"Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study","volume":"10","author":"Ge X","year":"2020","unstructured":"Ge X, Zheng L, Wang M, Du Y, Jiang J. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study. BMJ Open. 2020, 10:e036663. 10.1136\/bmjopen-2019-036663","journal-title":"BMJ Open"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84577-z","article-title":"The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017","volume":"11","author":"Zhai M","year":"2021","unstructured":"Zhai M, Liu Z, Long J, et al.. The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017. Sci Rep. 2021, 11:5195. 10.1038\/s41598-021-84577-z","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.18295\/squmj.2020.20.03.011","article-title":"Hepatocellular carcinoma in Oman: an analysis of 284 cases","volume":"20","author":"Al-Naamani K","year":"2020","unstructured":"Al-Naamani K, Al-Hashami Z, Al-Siyabi O, et al.. Hepatocellular carcinoma in Oman: an analysis of 284 cases. Sultan Qaboos Univ Med J. 2020, 20:e316-22. 10.18295\/squmj.2020.20.03.011","journal-title":"Sultan Qaboos Univ Med J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.112","article-title":"The metabolic basis of nonalcoholic steatohepatitis","volume":"3","author":"Chakravarthy MV","year":"2020","unstructured":"Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab. 2020, 3:e00112. 10.1002\/edm2.112","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.634344","article-title":"Fructose and non-alcoholic steatohepatitis","volume":"12","author":"Roeb E","year":"2021","unstructured":"Roeb E, Weiskirchen R. Fructose and non-alcoholic steatohepatitis. Front Pharmacol. 2021, 12:634344. 10.3389\/fphar.2021.634344","journal-title":"Front Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent insights into the pathogenesis of nonalcoholic fatty liver disease","volume":"13","author":"Arab JP","year":"2018","unstructured":"Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol. 2018, 13:321-50. 10.1146\/annurev-pathol-020117-043617","journal-title":"Annu Rev Pathol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith GI","year":"2020","unstructured":"Smith GI, Shankaran M, Yoshino M, et al.. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020, 130:1453-60. 10.1172\/JCI134165","journal-title":"J Clin Invest"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1586\/egh.11.19","article-title":"Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?","volume":"5","author":"Lonardo A","year":"2011","unstructured":"Lonardo A, Bellentani S, Ratziu V, Loria P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?. Expert Rev Gastroenterol Hepatol. 2011, 5:279-89. 10.1586\/egh.11.19","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11030155","article-title":"Insulin resistance across the spectrum of nonalcoholic fatty liver disease","volume":"11","author":"Armandi A","year":"2021","unstructured":"Armandi A, Rosso C, Caviglia GP, Bugianesi E. Insulin resistance across the spectrum of nonalcoholic fatty liver disease. Metabolites. 2021, 11:155. 10.3390\/metabo11030155","journal-title":"Metabolites"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1412427","article-title":"Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease","volume":"371","author":"Shin SW","year":"2014","unstructured":"Shin SW, Lee SJ. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014, 371:2237-8. 10.1056\/NEJMc1412427","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani A","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021, 70:962-9. 10.1136\/gutjnl-2020-322572","journal-title":"Gut"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.2933","article-title":"The carbohydrate-insulin model of obesity: beyond \"Calories In, Calories Out\"","volume":"178","author":"Ludwig DS","year":"2018","unstructured":"Ludwig DS, Ebbeling CB. The carbohydrate-insulin model of obesity: beyond \"Calories In, Calories Out\". JAMA Intern Med. 2018, 178:1098-103. 10.1001\/jamainternmed.2018.2933","journal-title":"JAMA Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1797-8","article-title":"The integrative biology of type 2 diabetes","volume":"576","author":"Roden M","year":"2019","unstructured":"Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019, 576:51-60. 10.1038\/s41586-019-1797-8","journal-title":"Nature"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1263","article-title":"Temporal associations among body mass index, fasting insulin, and systemic inflammation: a systematic review and meta-analysis","volume":"4","author":"Wiebe N","year":"2021","unstructured":"Wiebe N, Ye F, Crumley ET, Bello A, Stenvinkel P, Tonelli M. Temporal associations among body mass index, fasting insulin, and systemic inflammation: a systematic review and meta-analysis. JAMA Netw Open. 2021, 4:e211263. 10.1001\/jamanetworkopen.2021.1263","journal-title":"JAMA Netw Open"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60619-X","article-title":"Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study","volume":"373","author":"Tab\u00e1k AG","year":"2009","unstructured":"Tab\u00e1k AG, Jokela M, Akbaraly TN, Brunner EJ, Kivim\u00e4ki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009, 373:2215-21. 10.1016\/S0140-6736(09)60619-X","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)60865-5","article-title":"Impending type 2 diabetes","volume":"373","author":"Matthews DR","year":"2009","unstructured":"Matthews DR, Levy JC. Impending type 2 diabetes. Lancet. 2009, 373:2178-9. 10.1016\/s0140-6736(09)60865-5","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00071","article-title":"Type 2 diabetes: when does it start?","volume":"2","author":"Sagesaka H","year":"2018","unstructured":"Sagesaka H, Sato Y, Someya Y, et al.. Type 2 diabetes: when does it start?. J Endocr Soc. 2018, 2:476-84. 10.1210\/js.2018-00071","journal-title":"J Endocr Soc"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.suppl_3.s16","article-title":"Five stages of evolving beta-cell dysfunction during progression to diabetes","volume":"53 Suppl 3","author":"Weir GC","year":"2004","unstructured":"Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004, 53 Suppl 3:S16-21. 10.2337\/diabetes.53.suppl_3.s16","journal-title":"Diabetes"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1042\/CS20140553","article-title":"Normal weight individuals who develop type 2 diabetes: the personal fat threshold","volume":"128","author":"Taylor R","year":"2015","unstructured":"Taylor R, Holman RR. Normal weight individuals who develop type 2 diabetes: the personal fat threshold. Clin Sci (Lond). 2015, 128:405-10. 10.1042\/CS20140553","journal-title":"Clin Sci (Lond)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1062","article-title":"Insights into metabolic mechanisms and their application in the treatment of NASH","volume":"17","author":"White PJ","year":"2021","unstructured":"White PJ, Abdelmalek MF. Insights into metabolic mechanisms and their application in the treatment of NASH. Clin Liver Dis (Hoboken). 2021, 17:29-32. 10.1002\/cld.1062","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.2337\/db20-0377","article-title":"Obesity is associated with increased basal and postprandial \u03b2-cell insulin secretion even in the absence of insulin resistance","volume":"69","author":"van Vliet S","year":"2020","unstructured":"van Vliet S, Koh HE, Patterson BW, et al.. Obesity is associated with increased basal and postprandial \u03b2-cell insulin secretion even in the absence of insulin resistance. Diabetes. 2020, 69:2112-9. 10.2337\/db20-0377","journal-title":"Diabetes"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.2337\/ds19-0070","article-title":"Low-carbohydrate and very-low-carbohydrate diets in patients with diabetes","volume":"33","author":"Merrill JD","year":"2020","unstructured":"Merrill JD, Soliman D, Kumar N, Lim S, Shariff AI, Yancy WS Jr. Low-carbohydrate and very-low-carbohydrate diets in patients with diabetes. Diabetes Spectr. 2020, 33:133-42. 10.2337\/ds19-0070","journal-title":"Diabetes Spectr"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehb.2019.100818","article-title":"U.S. obesity as delayed effect of excess sugar","volume":"36","author":"Alexander Bentley R","year":"2020","unstructured":"Alexander Bentley R, Ruck DJ, Fouts HN. U.S. obesity as delayed effect of excess sugar. Econ Hum Biol. 2020, 36:100818. 10.1016\/j.ehb.2019.100818","journal-title":"Econ Hum Biol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.31232\/osf.io\/w3zh2","article-title":"Ultra-processed diets cause excess calorie intake and weight gain: a one-month inpatient randomized controlled trial of ad libitum food intake","volume":"30","author":"Hall KD","year":"2019","unstructured":"Hall KD. Ultra-processed diets cause excess calorie intake and weight gain: a one-month inpatient randomized controlled trial of ad libitum food intake. Cell Metab. 2019, 30:67-77.e3. 10.31232\/osf.io\/w3zh2","journal-title":"Cell Metab"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.5394","article-title":"Sugar industry and coronary heart disease research: a historical analysis of internal idustry documents","volume":"176","author":"Kearns CE","year":"2016","unstructured":"Kearns CE, Schmidt LA, Glantz SA. Sugar industry and coronary heart disease research: a historical analysis of internal idustry documents. JAMA Intern Med. 2016, 176:1680-5. 10.1001\/jamainternmed.2016.5394","journal-title":"JAMA Intern Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2014.04.028","article-title":"Hyperinsulinemic syndrome: the metabolic syndrome is broader than you think","volume":"156","author":"Kelly CT","year":"2014","unstructured":"Kelly CT, Mansoor J, Dohm GL, Chapman WH 3rd, Pender JR 4th, Pories WJ. Hyperinsulinemic syndrome: the metabolic syndrome is broader than you think. Surgery. 2014, 156:405-11. 10.1016\/j.surg.2014.04.028","journal-title":"Surgery"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323188","article-title":"NAFLD-related mortality: simple hepatic steatosis is not as 'benign' as thought","volume":"70","author":"Tilg H","year":"2021","unstructured":"Tilg H, Targher G. NAFLD-related mortality: simple hepatic steatosis is not as 'benign' as thought. Gut. 2021, 70:1212-3. 10.1136\/gutjnl-2020-323188","journal-title":"Gut"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review","volume":"110","author":"Kasper P","year":"2021","unstructured":"Kasper P, Martin A, Lang S, K\u00fctting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021, 110:921-37. 10.1007\/s00392-020-01709-7","journal-title":"Clin Res Cardiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2021.100320","article-title":"Hepatic steatosis and respiratory diseases: a new panorama","volume":"24","author":"Botello-Manilla AE","year":"2021","unstructured":"Botello-Manilla AE, L\u00f3pez-S\u00e1nchez GN, Ch\u00e1vez-Tapia NC, Uribe M, Nu\u00f1o-L\u00e1mbarri N. Hepatic steatosis and respiratory diseases: a new panorama. Ann Hepatol. 2021, 24:100320. 10.1016\/j.aohep.2021.100320","journal-title":"Ann Hepatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne CD","year":"2020","unstructured":"Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020, 72:785-801. 10.1016\/j.jhep.2020.01.013","journal-title":"J Hepatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6678142","article-title":"Association between nonalcoholic fatty liver disease and endocrinopathies: clinical implications","volume":"2021","author":"Singeap AM","year":"2021","unstructured":"Singeap AM, Stanciu C, Huiban L, et al.. Association between nonalcoholic fatty liver disease and endocrinopathies: clinical implications. Can J Gastroenterol Hepatol. 2021, 2021:6678142. 10.1155\/2021\/6678142","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2015.050","article-title":"Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation","volume":"6","author":"Bhatt BD","year":"2015","unstructured":"Bhatt BD, Lukose T, Siegel AB, Brown RS Jr, Verna EC. Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation. J Gastrointest Oncol. 2015, 6:459-68. 10.3978\/j.issn.2078-6891.2015.050","journal-title":"J Gastrointest Oncol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2019.12.07","article-title":"The \"obese liver\" and gastrointestinal cancer risk","volume":"5","author":"Lonardo A","year":"2020","unstructured":"Lonardo A, Roncucci L. The \"obese liver\" and gastrointestinal cancer risk. Transl Gastroenterol Hepatol. 2020, 5:44. 10.21037\/tgh.2019.12.07","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study","volume":"71","author":"Allen AM","year":"2019","unstructured":"Allen AM, Hicks SB, Mara KC, Larson JJ, Therneau TM. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study. J Hepatol. 2019, 71:1229-36. 10.1016\/j.jhep.2019.08.018","journal-title":"J Hepatol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31845","article-title":"Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study [PREPRINT]","author":"Simon TG","year":"2021","unstructured":"Simon TG, Roelstraete B, Sharma R, Khalili H, Hagstr\u00f6m H, Ludvigsson JF. Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study [PREPRINT]. Hepatology. 2021, 10.1002\/hep.31845","journal-title":"Hepatology"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","author":"Mantovani A","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. 2021, gutjnl-2021-324191. 10.1136\/gutjnl-2021-324191","journal-title":"Gut"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017098","article-title":"Obesity and nonalcoholic fatty liver disease associated with adenocarcinoma in patients with lung cancer","volume":"98","author":"Zhu CY","year":"2019","unstructured":"Zhu CY, Qu JC, Cao HX, Chen GY, Shi YH, Fan JG. Obesity and nonalcoholic fatty liver disease associated with adenocarcinoma in patients with lung cancer. Medicine (Baltimore). 2019, 98:e17098. 10.1097\/MD.0000000000017098","journal-title":"Medicine (Baltimore)"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200304000-00015","article-title":"Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study","volume":"36","author":"S\u00f8rensen HT","year":"2003","unstructured":"S\u00f8rensen HT, Mellemkjaer L, Jepsen P, Thulstrup AM, Baron J, Olsen JH, Vilstrup H. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol. 2003, 36:356-9. 10.1097\/00004836-200304000-00015","journal-title":"J Clin Gastroenterol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-020-01288-6","article-title":"Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis","volume":"19","author":"Liu SS","year":"2020","unstructured":"Liu SS, Ma XF, Zhao J, Du SX, Zhang J, Dong MZ, Xin YN. Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis. Lipids Health Dis. 2020, 19:118. 10.1186\/s12944-020-01288-6","journal-title":"Lipids Health Dis"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.584396","article-title":"Distinct cause of death profiles of hospitalized non-alcoholic fatty liver disease: a 10 years' cross-sectional multicenter study in China","volume":"7","author":"Lin Y","year":"2020","unstructured":"Lin Y, Gong X, Li X, et al.. Distinct cause of death profiles of hospitalized non-alcoholic fatty liver disease: a 10 years' cross-sectional multicenter study in China. Front Med (Lausanne). 2020, 7:584396. 10.3389\/fmed.2020.584396","journal-title":"Front Med (Lausanne)"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.4103\/ijmpo.ijmpo_117_20","article-title":"Obesity-related cancers: the coming epidemic","volume":"41","author":"Venniyoor A","year":"2020","unstructured":"Venniyoor A. Obesity-related cancers: the coming epidemic. Indian J Med Paediatr Oncol. 2020, 41:328-34. 10.4103\/ijmpo.ijmpo_117_20","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer--viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan B","year":"2016","unstructured":"Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer--viewpoint of the IARC Working Group. N Engl J Med. 2016, 375:794-8. 10.1056\/NEJMsr1606602","journal-title":"N Engl J Med"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1186\/s40608-018-0205-5","article-title":"Use of various obesity measurement and classification methods in occupational safety and health research: a systematic review of the literature","volume":"5","author":"Ghesmaty Sangachin M","year":"2018","unstructured":"Ghesmaty Sangachin M, Cavuoto LA, Wang Y. Use of various obesity measurement and classification methods in occupational safety and health research: a systematic review of the literature. BMC Obes. 2018, 5:28. 10.1186\/s40608-018-0205-5","journal-title":"BMC Obes"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-20-0633","article-title":"Cancer risk in normal weight individuals with metabolic obesity: a narrative review","volume":"14","author":"Liu B","year":"2021","unstructured":"Liu B, Giffney HE, Arthur RS, Rohan TE, Dannenberg AJ. Cancer risk in normal weight individuals with metabolic obesity: a narrative review. Cancer Prev Res (Phila). 2021, 14:509-20. 10.1158\/1940-6207.CAPR-20-0633","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05484-6","article-title":"Are people with metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK Biobank participants [PREPRINT]","author":"Zhou Z","year":"2021","unstructured":"Zhou Z, Macpherson J, Gray SR, et al.. Are people with metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK Biobank participants [PREPRINT]. Diabetologia. 2021, 10.1007\/s00125-021-05484-6","journal-title":"Diabetologia"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-021-05412-y","article-title":"Gastric bypass compared with sleeve gastrectomy for nonalcoholic fatty liver disease: a dystematic review and meta-analysis","volume":"31","author":"de Brito E Silva MB","year":"2021","unstructured":"de Brito E Silva MB, Tustumi F, de Miranda Neto AA, Dantas AC, Santo MA, Cecconello I. Gastric bypass compared with sleeve gastrectomy for nonalcoholic fatty liver disease: a dystematic review and meta-analysis. Obes Surg. 2021, 31:2762-72. 10.1007\/s11695-021-05412-y","journal-title":"Obes Surg"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz054","article-title":"Intentional weight loss and obesity-related cancer risk","volume":"3","author":"Luo J","year":"2019","unstructured":"Luo J, Hendryx M, Manson JE, et al.. Intentional weight loss and obesity-related cancer risk. JNCI Cancer Spectr. 2019, 3:pkz054. 10.1093\/jncics\/pkz054","journal-title":"JNCI Cancer Spectr"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-017-0185-8","article-title":"The most important questions in cancer research and clinical oncology-Question 2-5. Obesity-related cancers: more questions than answers","volume":"36","author":"Venniyoor A","year":"2017","unstructured":"Venniyoor A. The most important questions in cancer research and clinical oncology-Question 2-5. Obesity-related cancers: more questions than answers. Chin J Cancer. 2017, 36:18. 10.1186\/s40880-017-0185-8","journal-title":"Chin J Cancer"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1006","article-title":"Molecular mechanisms linking nonalcoholic steatohepatitis to cancer","volume":"17","author":"Wegermann K","year":"2021","unstructured":"Wegermann K, Hyun J, Diehl AM. Molecular mechanisms linking nonalcoholic steatohepatitis to cancer. Clin Liver Dis (Hoboken). 2021, 17:6-10. 10.1002\/cld.1006","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0329-9","article-title":"Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer","volume":"16","author":"Hopkins BD","year":"2020","unstructured":"Hopkins BD, Goncalves MD, Cantley LC. Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer. Nat Rev Endocrinol. 2020, 16:276-83. 10.1038\/s41574-020-0329-9","journal-title":"Nat Rev Endocrinol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.56","article-title":"Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Meex RC","year":"2017","unstructured":"Meex RC, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017, 13:509-20. 10.1038\/nrendo.2017.56","journal-title":"Nat Rev Endocrinol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1210\/er.2019-00034","article-title":"The liver as an endocrine organ-linking NAFLD and insulin resistance","volume":"40","author":"Watt MJ","year":"2019","unstructured":"Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019, 40:1367-93. 10.1210\/er.2019-00034","journal-title":"Endocr Rev"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00262.2017","article-title":"The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans","volume":"314","author":"Peter A","year":"2018","unstructured":"Peter A, Kovarova M, Staiger H, et al.. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. Am J Physiol Endocrinol Metab. 2018, 314:E266-73. 10.1152\/ajpendo.00262.2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S245178","article-title":"Review of research on the role of irisin in tumors","volume":"13","author":"Zhang D","year":"2020","unstructured":"Zhang D, Tan X, Tang N, Huang F, Chen Z, Shi G. Review of research on the role of irisin in tumors. Onco Targets Ther. 2020, 13:4423-30. 10.2147\/OTT.S245178","journal-title":"Onco Targets Ther"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-019-0041-z","article-title":"Metabolic messengers: adiponectin","volume":"1","author":"Straub LG","year":"2019","unstructured":"Straub LG, Scherer PE. Metabolic messengers: adiponectin. Nat Metab. 2019, 1:334-9. 10.1038\/s42255-019-0041-z","journal-title":"Nat Metab"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.6612","article-title":"Fatty liver is a risk factor for liver metastasis in Chinese patients with non-small cell lung cancer","volume":"7","author":"Wu W","year":"2019","unstructured":"Wu W, Liao H, Ye W, Li X, Zhang J, Bu J. Fatty liver is a risk factor for liver metastasis in Chinese patients with non-small cell lung cancer. PeerJ. 2019, 7:e6612. 10.7717\/peerj.6612","journal-title":"PeerJ"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07980-9","article-title":"Baseline liver steatosis has no impact on liver metastases and overall survival in rectal cancer patients","volume":"21","author":"Besutti G","year":"2021","unstructured":"Besutti G, Damato A, Venturelli F, et al.. Baseline liver steatosis has no impact on liver metastases and overall survival in rectal cancer patients. BMC Cancer. 2021, 21:253. 10.1186\/s12885-021-07980-9","journal-title":"BMC Cancer"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4411-5","article-title":"Fatty liver decreases the risk of liver metastasis in patients with breast cancer: a two-center cohort study","volume":"166","author":"Wu W","year":"2017","unstructured":"Wu W, Chen J, Ye W, Li X, Zhang J. Fatty liver decreases the risk of liver metastasis in patients with breast cancer: a two-center cohort study. Breast Cancer Res Treat. 2017, 166:289-97. 10.1007\/s10549-017-4411-5","journal-title":"Breast Cancer Res Treat"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-013-1656-2","article-title":"Hepatic steatosis is associated with lower incidence of liver metastasis from colorectal cancer","volume":"28","author":"Murono K","year":"2013","unstructured":"Murono K, Kitayama J, Tsuno NH, et al.. Hepatic steatosis is associated with lower incidence of liver metastasis from colorectal cancer. Int J Colorectal Dis. 2013, 28:1065-72. 10.1007\/s00384-013-1656-2","journal-title":"Int J Colorectal Dis"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.7326\/L19-0635","article-title":"Lipodystrophic nonalcoholic fatty liver disease induced by immune checkpoint blockade","volume":"172","author":"Eigentler T","year":"2020","unstructured":"Eigentler T, Lomberg D, Machann J, Stefan N. Lipodystrophic nonalcoholic fatty liver disease induced by immune checkpoint blockade. Ann Intern Med. 2020, 172:836-7. 10.7326\/L19-0635","journal-title":"Ann Intern Med"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14889","article-title":"Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor","volume":"35","author":"Sawada K","year":"2020","unstructured":"Sawada K, Hayashi H, Nakajima S, Hasebe T, Fujiya M, Okumura T. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. J Gastroenterol Hepatol. 2020, 35:1042-8. 10.1111\/jgh.14889","journal-title":"J Gastroenterol Hepatol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa458","article-title":"Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index","volume":"105","author":"Pollack R","year":"2020","unstructured":"Pollack R, Ashash A, Cahn A, Rottenberg Y, Stern H, Dresner-Pollak R. Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index. J Clin Endocrinol Metab. 2020, 105:dgaa458. 10.1210\/clinem\/dgaa458","journal-title":"J Clin Endocrinol Metab"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-016-0539-4","article-title":"The obesity paradox in cancer: a review","volume":"18","author":"Lennon H","year":"2016","unstructured":"Lennon H, Sperrin M, Badrick E, Renehan AG. The obesity paradox in cancer: a review. Curr Oncol Rep. 2016, 18:56. 10.1007\/s11912-016-0539-4","journal-title":"Curr Oncol Rep"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0019","article-title":"Assessment of immune checkpoint inhibitors and genomic alterations by body mass index in advanced renal cell carcinoma","volume":"7","author":"Lalani AA","year":"2021","unstructured":"Lalani AA, Bakouny Z, Farah S, Donskov F, Dudani S, Heng DY, Choueiri TK. Assessment of immune checkpoint inhibitors and genomic alterations by body mass index in advanced renal cell carcinoma. JAMA Oncol. 2021, 7:773-5. 10.1001\/jamaoncol.2021.0019","journal-title":"JAMA Oncol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052628","article-title":"Impact of BMI on survival outcomes of immunotherapy in solid tumors: a systematic review","volume":"22","author":"Indini A","year":"2021","unstructured":"Indini A, Rijavec E, Ghidini M, et al.. Impact of BMI on survival outcomes of immunotherapy in solid tumors: a systematic review. Int J Mol Sci. 2021, 22:2628. 10.3390\/ijms22052628","journal-title":"Int J Mol Sci"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister D","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R, et al.. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021, 592:450-6. 10.1038\/s41586-021-03362-0","journal-title":"Nature"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2020.04.15","article-title":"Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases","volume":"9","author":"Zhou J","year":"2020","unstructured":"Zhou J, Zhou F, Chu X, et al.. Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases. Transl Lung Cancer Res. 2020, 9:316-24. 10.21037\/tlcr.2020.04.15","journal-title":"Transl Lung Cancer Res"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3747\/co.24.3133","article-title":"Effect of non-alcoholic liver disease on recurrence rate and liver regeneration after liver resection for colorectal liver metastases","volume":"24","author":"Molla NW","year":"2017","unstructured":"Molla NW, Hassanain MM, Fadel Z, et al.. Effect of non-alcoholic liver disease on recurrence rate and liver regeneration after liver resection for colorectal liver metastases. Curr Oncol. 2017, 24:e233-43. 10.3747\/co.24.3133","journal-title":"Curr Oncol"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100810","article-title":"Time to end weight stigma in healthcare","volume":"34","author":"Flint SW","year":"2021","unstructured":"Flint SW. Time to end weight stigma in healthcare. EClinicalMedicine. 2021, 34:100810. 10.1016\/j.eclinm.2021.100810","journal-title":"EClinicalMedicine"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez E","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al.. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015, 149:367-78.e5; quiz e14-5. 10.1053\/j.gastro.2015.04.005","journal-title":"Gastroenterology"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00588","article-title":"Therapeutic approaches to nonalcoholic fatty liver disease: exercise itervention and related mechanisms","volume":"9","author":"Takahashi H","year":"2018","unstructured":"Takahashi H, Kotani K, Tanaka K, Egucih Y, Anzai K. Therapeutic approaches to nonalcoholic fatty liver disease: exercise itervention and related mechanisms. Front Endocrinol (Lausanne). 2018, 9:588. 10.3389\/fendo.2018.00588","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0067","article-title":"Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH","volume":"26","author":"Hydes TJ","year":"2020","unstructured":"Hydes TJ, Ravi S, Loomba R, Gray ME. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. Clin Mol Hepatol. 2020, 26:383-400. 10.3350\/cmh.2020.0067","journal-title":"Clin Mol Hepatol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2017.08.012","article-title":"Maintenance of lost weight and long-term management of obesity","volume":"102","author":"Hall KD","year":"2018","unstructured":"Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Med Clin North Am. 2018, 102:183-97. 10.1016\/j.mcna.2017.08.012","journal-title":"Med Clin North Am"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1210\/er.2017-00111","article-title":"Obesity pathogenesis: an endocrine society scientific statement","volume":"38","author":"Schwartz MW","year":"2017","unstructured":"Schwartz MW, Seeley RJ, Zeltser LM, Drewnowski A, Ravussin E, Redman LM, Leibel RL. Obesity pathogenesis: an endocrine society scientific statement. Endocr Rev. 2017, 38:267-96. 10.1210\/er.2017-00111","journal-title":"Endocr Rev"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.03.021","article-title":"Bariatric surgery reduces cancer risk in adults with nonalcoholic fatty liver disease and severe obesity","volume":"161","author":"Rustgi VK","year":"2021","unstructured":"Rustgi VK, Li Y, Gupta K, Minacapelli CD, Bhurwal A, Catalano C, Elsaid MI. Bariatric surgery reduces cancer risk in adults with nonalcoholic fatty liver disease and severe obesity. Gastroenterology. 2021, 161:171-84.e10. 10.1053\/j.gastro.2021.03.021","journal-title":"Gastroenterology"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial","volume":"7","author":"Lean MEJ","year":"2019","unstructured":"Lean MEJ, Leslie WS, Barnes AC, et al.. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019, 7:34455. 10.1016\/s2213-8587(19)30068-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15618","article-title":"The significance of the Mediterranean diet in the management of non-alcoholic fatty liver disease: a systematic review","volume":"13","author":"Gosal H","year":"2021","unstructured":"Gosal H, Kaur H, Chakwop Ngassa H, Elmenawi KA, Anil V, Mohammed L. The significance of the Mediterranean diet in the management of non-alcoholic fatty liver disease: a systematic review. Cureus. 2021, 13:e15618. 10.7759\/cureus.15618","journal-title":"Cureus"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S276085","article-title":"Clinical impact of liraglutide as a treatment of obesity","volume":"13","author":"Alruwaili H","year":"2021","unstructured":"Alruwaili H, Dehestani B, le Roux CW. Clinical impact of liraglutide as a treatment of obesity. Clin Pharmacol. 2021, 13:53-60. 10.2147\/CPAA.S276085","journal-title":"Clin Pharmacol"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome PN","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al.. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021, 384:1113-24. 10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15141","article-title":"Role of glucagon-like peptide-1 receptor agonists in the management of non-alcoholic steatohepatitis: a clinical review article","volume":"13","author":"Ghazanfar H","year":"2021","unstructured":"Ghazanfar H, Kandhi SD, Nawaz I, et al.. Role of glucagon-like peptide-1 receptor agonists in the management of non-alcoholic steatohepatitis: a clinical review article. Cureus. 2021, 13:e15141. 10.7759\/cureus.15141","journal-title":"Cureus"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.12713","article-title":"Treatment of fatty liver disease: the present and the future","volume":"13","author":"Ramanan SP","year":"2021","unstructured":"Ramanan SP, Mohamed MW, Aung SS, Sange I, Hamid P. Treatment of fatty liver disease: the present and the future. Cureus. 2021, 13:e12713. 10.7759\/cureus.12713","journal-title":"Cureus"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.3390\/nu12051316","article-title":"Beyond body weight-loss: dietary strategies targeting intrahepatic fat in NAFLD","volume":"12","author":"Worm N","year":"2020","unstructured":"Worm N. Beyond body weight-loss: dietary strategies targeting intrahepatic fat in NAFLD. Nutrients. 2020, 12:1316. 10.3390\/nu12051316","journal-title":"Nutrients"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0000000000000762","article-title":"Beyond weight loss in nonalcoholic fatty liver disease: the role of carbohydrate restriction","volume":"24","author":"Risi R","year":"2021","unstructured":"Risi R, Tozzi R, Watanabe M. Beyond weight loss in nonalcoholic fatty liver disease: the role of carbohydrate restriction. Curr Opin Clin Nutr Metab Care. 2021, 24:349-53. 10.1097\/MCO.0000000000000762","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqaa332","article-title":"Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial","volume":"113","author":"Simons N","year":"2021","unstructured":"Simons N, Veeraiah P, Simons PI, et al.. Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial. Am J Clin Nutr. 2021, 113:391-400. 10.1093\/ajcn\/nqaa332","journal-title":"Am J Clin Nutr"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi R","year":"2021","unstructured":"Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2021, 18:373-92. 10.1038\/s41575-020-00408-y","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010716-104727","article-title":"Emerging pharmacological targets for the treatment of nonalcoholic fatty liver disease, insulin resistance, and type 2 diabetes","volume":"59","author":"Goedeke L","year":"2019","unstructured":"Goedeke L, Perry RJ, Shulman GI. Emerging pharmacological targets for the treatment of nonalcoholic fatty liver disease, insulin resistance, and type 2 diabetes. Annu Rev Pharmacol Toxicol. 2019, 59:65-87. 10.1146\/annurev-pharmtox-010716-104727","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal AJ","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al.. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010, 362:1675-85. 10.1056\/NEJMoa0907929","journal-title":"N Engl J Med"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial [PREPRINT]","author":"Gawrieh S","year":"2021","unstructured":"Gawrieh S, Noureddin M, Loo N, et al.. Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial [PREPRINT]. Hepatology. 2021, 10.1002\/hep.31843","journal-title":"Hepatology"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14572","article-title":"Early life famine exposure, adulthood obesity patterns and the risk of nonalcoholic fatty liver disease","volume":"40","author":"Qi H","year":"2020","unstructured":"Qi H, Hu C, Wang S, et al.. Early life famine exposure, adulthood obesity patterns and the risk of nonalcoholic fatty liver disease. Liver Int. 2020, 40:2694-705. 10.1111\/liv.14572","journal-title":"Liver Int"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129191","article-title":"Contribution of adipogenesis to healthy adipose tissue expansion in obesity","volume":"129","author":"Vishvanath L","year":"2019","unstructured":"Vishvanath L, Gupta RK. Contribution of adipogenesis to healthy adipose tissue expansion in obesity. J Clin Invest. 2019, 129:4022-31. 10.1172\/JCI129191","journal-title":"J Clin Invest"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31021","article-title":"Obesity-associated improvements in metabolic profile through expansion of adipose tissue","volume":"117","author":"Kim JY","year":"2007","unstructured":"Kim JY, van de Wall E, Laplante M, et al.. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007, 117:2621-37. 10.1172\/JCI31021","journal-title":"J Clin Invest"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.8.1863","article-title":"Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance","volume":"50","author":"de Souza CJ","year":"2001","unstructured":"de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes. 2001, 50:1863-71. 10.2337\/diabetes.50.8.1863","journal-title":"Diabetes"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14304","article-title":"Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: a hierarchical network meta-analysis","volume":"23","author":"Panunzi S","year":"2021","unstructured":"Panunzi S, Maltese S, Verrastro O, et al.. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: a hierarchical network meta-analysis. Diabetes Obes Metab. 2021, 23:980-90. 10.1111\/dom.14304","journal-title":"Diabetes Obes Metab"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101178","article-title":"Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH","volume":"46","author":"Goedeke L","year":"2021","unstructured":"Goedeke L, Shulman GI. Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH. Mol Metab. 2021, 46:101178. 10.1016\/j.molmet.2021.101178","journal-title":"Mol Metab"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1518424","article-title":"Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response","volume":"18","author":"Delaune V","year":"2018","unstructured":"Delaune V, Orci LA, Lacotte S, Peloso A, Schrenzel J, Lazarevic V, Toso C. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response. Expert Opin Biol Ther. 2018, 18:1061-71. 10.1080\/14712598.2018.1518424","journal-title":"Expert Opin Biol Ther"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14062","article-title":"Whole-body vibration for patients with nonalcoholic fatty liver disease: a 6-month prospective study","volume":"7","author":"Oh S","year":"2019","unstructured":"Oh S, Oshida N, Someya N, et al.. Whole-body vibration for patients with nonalcoholic fatty liver disease: a 6-month prospective study. Physiol Rep. 2019, 7:e14062. 10.14814\/phy2.14062","journal-title":"Physiol Rep"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.03.012","article-title":"Obesity therapeutics: the end of the beginning","volume":"33","author":"Gribble FM","year":"2021","unstructured":"Gribble FM, O'Rahilly S. Obesity therapeutics: the end of the beginning. Cell Metab. 2021, 33:705-6. 10.1016\/j.cmet.2021.03.012","journal-title":"Cell Metab"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes C","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018, 67:123-33. 10.1002\/hep.29466","journal-title":"Hepatology"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.316337","article-title":"Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases","volume":"126","author":"Cai J","year":"2020","unstructured":"Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, Li H. Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases. Circ Res. 2020, 126:679-704. 10.1161\/CIRCRESAHA.119.316337","journal-title":"Circ Res"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13419","article-title":"Nonalcoholic fatty liver disease: an emerging driver of hypertension","volume":"75","author":"Zhao YC","year":"2020","unstructured":"Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension. 2020, 75:275-84. 10.1161\/HYPERTENSIONAHA.119.13419","journal-title":"Hypertension"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30431-9","article-title":"Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records","volume":"9","author":"Pearson-Stuttard J","year":"2021","unstructured":"Pearson-Stuttard J, Bennett J, Cheng YJ, Vamos EP, Cross AJ, Ezzati M, Gregg EW. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 2021, 9:165-73. 10.1016\/S2213-8587(20)30431-9","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/67151-the-troubling-link-between-non-alcoholic-fatty-liver-disease-nafld-and-extrahepatic-cancers-ehc","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:58Z","timestamp":1707506998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/67151-the-troubling-link-between-non-alcoholic-fatty-liver-disease-nafld-and-extrahepatic-cancers-ehc"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":120,"URL":"https:\/\/doi.org\/10.7759\/cureus.17320","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}